Age-related Macular Degeneration Digital Marketing Trends Report 2024: Metrics of Pharma Assets in AMD Including Branded Websites for Patients and HCPs and Unbranded Sites [Yahoo! Finance]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Yahoo! Finance
This report assesses key digital marketing metrics of pharma assets in AMD including branded websites for patients and HCPs and unbranded sites. Metrics include website traffic volume, engagement, and source, DDA and paid SEO. Countries include the US and EUCAN. Genentech's Vabysmo.com achieved the highest total traffic across branded age-related macular degeneration (AMD) patient sites in the US, with over two million visits from June 2023 to May 2024. This was followed by Bayer's Eylea.us (353,000 visits). Overall, the highest proportion of traffic to branded AMD websites originated from direct sources, followed by organic. There was minimal paid search engine optimization (SEO) detected across most branded sites in the US. Vabysmo.com was supported by the most paid SEO at over 1,726 keywords, followed by Syfovre.com at 1,130 keywords. Genentech spent the most on Digital Display Advertising (DDA) for Vabysmo.com, at $640,000. Genentech's Vabysmo-hcp.com achieved the highest t
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses [Yahoo! Finance]Yahoo! Finance
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Coherus BioSciences, Inc. (NASDAQ: CHRS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
CHRS
Earnings
- 8/8/24 - Beat
CHRS
Sec Filings
- 9/13/24 - Form 8-K
- 8/9/24 - Form 4
- 8/8/24 - Form S-8
- CHRS's page on the SEC website